149 related articles for article (PubMed ID: 37667445)
1. Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib.
van der Veen L; Schmitt M; Deken MA; Lahn M
Int J Toxicol; 2023 Dec; 42(6):515-534. PubMed ID: 37667445
[TBL] [Abstract][Full Text] [Related]
2. The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition.
Kalla C; Ott G; Finotello F; Niewola-Staszkowska K; Conza GD; Lahn M; van der Veen L; Schüler J; Falkenstern-Ge R; Kopecka J; Riganti C
Transl Oncol; 2024 May; 43():101857. PubMed ID: 38412661
[TBL] [Abstract][Full Text] [Related]
3. Quantitative systems pharmacology model-based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3-kinase inhibitors.
Gadkar K; Friedrich C; Hurez V; Ruiz ML; Dickmann L; Kumar Jolly M; Schutt L; Jin J; Ware JA; Ramanujan S
CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):616-627. PubMed ID: 34850607
[TBL] [Abstract][Full Text] [Related]
4. Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models.
Moreno O; Wood J
Target Oncol; 2019 Oct; 14(5):603-611. PubMed ID: 31506873
[TBL] [Abstract][Full Text] [Related]
5. Characterizing Pharmacokinetic-Pharmacodynamic Relationships and Efficacy of PI3K
McLeod RL; Gil MA; Chen D; Cabal A; Katz J; Methot J; Woodhouse JD; Dorosh L; Geda P; Mehta K; Cicmil M; Baltus GA; Bass A; Houshyar H; Caniga M; Yu H; Gervais F; Alves S; Shah S
J Pharmacol Exp Ther; 2019 May; 369(2):223-233. PubMed ID: 30804001
[TBL] [Abstract][Full Text] [Related]
6. Structurally novel PI3Kδ/γ dual inhibitors characterized by a seven-membered spirocyclic spacer: The SARs investigation and PK evaluation.
Tao Q; Chen Y; Liang X; Hu Y; Li J; Fang F; Wang H; Meng C; Liang J; Ma X; Gui S
Eur J Med Chem; 2020 Apr; 191():112143. PubMed ID: 32078865
[TBL] [Abstract][Full Text] [Related]
7. Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia.
Witkowska M; Majchrzak A; Robak P; Wolska-Washer A; Robak T
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):617-633. PubMed ID: 37714711
[TBL] [Abstract][Full Text] [Related]
8. IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.
Johnson Z; Tarantelli C; Civanelli E; Cascione L; Spriano F; Fraser A; Shah P; Nomanbhoy T; Napoli S; Rinaldi A; Niewola-Staszkowska K; Lahn M; Perrin D; Wenes M; Migliorini D; Bertoni F; van der Veen L; Di Conza G
Cancer Res Commun; 2023 Apr; 3(4):576-591. PubMed ID: 37066023
[TBL] [Abstract][Full Text] [Related]
9. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
[TBL] [Abstract][Full Text] [Related]
10. Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor.
Nylander S; Kull B; Björkman JA; Ulvinge JC; Oakes N; Emanuelsson BM; Andersson M; Skärby T; Inghardt T; Fjellström O; Gustafsson D
J Thromb Haemost; 2012 Oct; 10(10):2127-36. PubMed ID: 22906130
[TBL] [Abstract][Full Text] [Related]
11. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.
Zhang X; Duan YT; Wang Y; Zhao XD; Sun YM; Lin DZ; Chen Y; Wang YX; Zhou ZW; Liu YX; Jiang LH; Geng MY; Ding J; Meng LH
Acta Pharmacol Sin; 2022 Jan; 43(1):209-219. PubMed ID: 33782541
[TBL] [Abstract][Full Text] [Related]
12. INCB040093 Is a Novel PI3K
Shin N; Li YL; Mei S; Wang KH; Hall L; Katiyar K; Wang Q; Yang G; Rumberger B; Leffet L; He X; Rupar M; Bowman K; Favata M; Li J; Liu M; Li Y; Covington M; Koblish H; Soloviev M; Shuey D; Burn T; Diamond S; Fridman J; Combs A; Yao W; Yeleswaram S; Hollis G; Vaddi K; Huber R; Newton R; Scherle P
J Pharmacol Exp Ther; 2018 Jan; 364(1):120-130. PubMed ID: 29127109
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856.
Perreault S; Chandrasekhar J; Cui ZH; Evarts J; Hao J; Kaplan JA; Kashishian A; Keegan KS; Kenney T; Koditek D; Lad L; Lepist EI; McGrath ME; Patel L; Phillips B; Therrien J; Treiberg J; Yahiaoui A; Phillips G
J Med Chem; 2017 Feb; 60(4):1555-1567. PubMed ID: 28106991
[TBL] [Abstract][Full Text] [Related]
14. Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase
Begg M; Edwards CD; Hamblin JN; Pefani E; Wilson R; Gilbert J; Vitulli G; Mallett D; Morrell J; Hingle MI; Uddin S; Ehtesham F; Marotti M; Harrell A; Newman CF; Fernando D; Clark J; Cahn A; Hessel EM
J Pharmacol Exp Ther; 2019 Jun; 369(3):443-453. PubMed ID: 30940692
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
Britten CD; Adjei AA; Millham R; Houk BE; Borzillo G; Pierce K; Wainberg ZA; LoRusso PM
Invest New Drugs; 2014 Jun; 32(3):510-7. PubMed ID: 24395457
[TBL] [Abstract][Full Text] [Related]
16. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
[No Abstract] [Full Text] [Related]
17. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
Lang F; Wunderle L; Badura S; Schleyer E; Brüggemann M; Serve H; Schnittger S; Gökbuget N; Pfeifer H; Wagner S; Ashelford K; Bug G; Ottmann OG
BMC Pharmacol Toxicol; 2020 Sep; 21(1):70. PubMed ID: 32993794
[TBL] [Abstract][Full Text] [Related]
18. An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome.
Begg M; Amour A; Jarvis E; Tang T; Franco SS; Want A; Beerahee M; Fernando D; Karkera Y; Sander C; Southworth T; Singh D; Clark J; Nejentsev S; Okkenhaug K; Condliffe A; Chandra A; Cahn A; Hall EB
Pulm Pharmacol Ther; 2023 Apr; 79():102201. PubMed ID: 36841351
[TBL] [Abstract][Full Text] [Related]
19. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
[TBL] [Abstract][Full Text] [Related]
20. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
